← All trials
NCT03002012
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2017
- Primary completion
- Apr 1, 2021
- Completion date
- Oct 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of MinnesotaLead sponsor
- University of MinnesotaStudy director
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Mbarara University of Science and TechnologyCollaborator
- Infectious Disease Institute, Kampala, UgandaStudy director
- Infectious Disease Institute, Kampala, UgandaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.